Detailed Information on Publication Record
2018
Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response
KOVÁČOVÁ, Júlia, Jaroslav JURÁČEK, Alexandr POPRACH, T. BUCHLER, J. KOPECKY et. al.Basic information
Original name
Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response
Authors
KOVÁČOVÁ, Júlia (703 Slovakia, belonging to the institution), Jaroslav JURÁČEK (203 Czech Republic, belonging to the institution), Alexandr POPRACH (203 Czech Republic, belonging to the institution), T. BUCHLER (203 Czech Republic), J. KOPECKY (203 Czech Republic), O. FIALA (203 Czech Republic), Marek SVOBODA (203 Czech Republic, belonging to the institution) and Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution)
Edition
Anticancer Research, Athens, International Institute of Anticancer Research, 2018, 0250-7005
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
Greece
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 1.935
RIV identification code
RIV/00216224:14740/18:00106955
Organization unit
Central European Institute of Technology
UT WoS
000449923200046
Keywords in English
Renal cell carcinoma; microRNA; sunitinib; therapy response; prediction
Tags
Tags
International impact, Reviewed
Změněno: 13/3/2019 13:00, Mgr. Pavla Foltynová, Ph.D.
Abstract
V originále
Background/Aim: Targeted therapy with the tyrosine kinase inhibitor sunitinib is used in the first line of metastatic renal cell carcinoma (mRCC) treatment. The aim of the present study was independent validation of microRNAs (miRNAs) identified in previous studies as biomarkers predicting response to sunitinib therapy. Materials and Methods: Based on a literature search, 10 miRNAs were chosen from six relevant studies as candidates for validation: miR-155, miR-484, miR-221, miR-222 , miR-425 , miR-133, miR-410, miR-141, miR-628 and miR-942. Validation of these miRNAs was performed on cohort of 56 patients with mRCC with extremely good or poor response responses to sunitinib treatment using quantitative reverse transcription-polymerase chain reaction. Patients were divided into either responding (n=24) or non-responding (n=32) groups to sunitinib treatment according to Response Evaluation Criteria in Solid Tumors and progression free survival (PFS). All patients in the responding group had PFS longer than 18 months, PFS of non-responders was shorter than 6 months in all cases. Results: miR-942 and miR-133 were confirmed as being differentially expressed in tumors of responding and non-responding patients. It was not possible to validate the predictive value of other tested miRNAs, however, expression of miR-221 and miR-425 tended to be positively associated with therapeutic response (p<0.1). We further developed a model based on the combination of miR-942 and miR-133 expression, that enabled identification of non-responding patients with mRCC with sensitivity of 78% and specificity of 79% (area under the curve=0.8071). Conclusion: Following further independent validation, detection of these miRNAs may prevent unnecessary and costly approaches to therapy in non-responding patients with mRCC.
Links
| NV15-34678A, research and development project |
|